PatientsVille.com Logo

VISUAL IMPAIRMENT and Viagra

PatientsVille

VISUAL IMPAIRMENT Symptoms and Causes

If you have low vision, eyeglasses, contact lenses, medicine, or surgery may not help. Activities like reading, shopping, cooking, writing, and watching TV may be hard to do. The leading causes of low vision and blindness in the United States are age-related eye diseases: macular degeneration, cataract and glaucoma. Other eye disorders, eye injuries, and birth defects can also cause vision loss.

Whatever the cause, lost vision cannot be restored. It can, however, be managed. A loss of vision means that you may have to reorganize your life and learn new ways of doing things. If you have some vision, visual aids such as special glasses and large print books can make life easier. There are also devices to help those with no vision, like text-reading software and braille books.

The sooner vision loss or eye disease is found and treated, the greater your chances of keeping your remaining vision. You should have regular comprehensive eye exams by an eye care professional.

NIH: National Eye Institute

Check out the latest treatments for VISUAL IMPAIRMENT

VISUAL IMPAIRMENT treatment research studies

Viagra clinical trials, surveys and public health registries


Find Drug Side Effect reports



Viagra Side Effects

Headache (505)
Erection Increased (390)
Flushing (324)
Optic Ischaemic Neuropathy (314)
Erectile Dysfunction (300)
Vision Blurred (278)
Hypertension (219)
Dizziness (211)
Prostate Cancer (194)
Visual Acuity Reduced (189)
Nasal Congestion (184)
Incorrect Dose Administered (178)
Blood Cholesterol Increased (173)
Penis Disorder (172)
Death (168)
Myocardial Infarction (165)
Cyanopsia (160)
Dyspnoea (145)
Feeling Abnormal (141)
Cerebrovascular Accident (134)
Blood Pressure Increased (95)
Chest Pain (93)
Visual Field Defect (92)
Diabetes Mellitus (92)
Malaise (83)
Nausea (80)
Pain (78)
Penile Pain (77)
Cataract (75)
Loss Of Consciousness (73)
Heart Rate Increased (72)
Depression (71)
Tinnitus (70)
Condition Aggravated (69)
Off Label Use (68)
Feeling Hot (68)
Visual Impairment (67)
Abdominal Discomfort (66)
Anxiety (66)
Visual Disturbance (65)
Erythema (64)
Dyspepsia (64)
Fall (62)
Ejaculation Disorder (60)
Fatigue (60)
Coronary Artery Occlusion (58)
Weight Decreased (54)
Deafness (54)
Blood Testosterone Decreased (53)
Hypotension (53)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Blepharospasm.

<span style='color: #808080;'><b>What do You think about Vision impairment and blindness?</b>

49yo female, 2/7 days use. Dose 15mg daily, after food. Experiencing severe headaches, visual disterbances, intermittent confusion, visual dreams/ hallucinations, exhaustion.

After about one month on the monthly dosage of Actonel I experienced jaw pain, muscle and joint pain and visual disturbances. Doctor wants to put me on Boniva. I've already tried Fosomax which caused me to have difficulty swallowi

Does long times usage of Concor 5mg cause any function in my health like memory impairment ?

Ever since I was on Sensipar ive been getting Migraines.'Visual first then Migrain following

I am a 67 yr old female, was prescribed Istn in 1990, and had no problem until two years ago. I then started to experience quite severe side effects, headaches, dizziness, nausea, visual disturbances, fatigue, anxiety among others. Since then my doct

I experienced a severe visual impairment, white sparkling lights to point of sight loss, distorted audio , near loss of bodily functions, severe h/a, sweating, chest pains, taste of the medication? in my mouth, unable to respond or move. It was horri

I have been taking crestor for about four years for highly elevated hdl. First 20mg now 10mg and am increasingly concerned that increased lethergy, cognitive impairment - short term memory loss and aphasia as well as chronic muscle ache may be a resu

I have been taking Pariet for over 6 months &amp; just realised I must be suffering side effects...reoccuring Flu symptoms &amp; Rhinitis, occasional leg cramps &amp; awakening with visual disturbances.

I have been using Garasone drops and recently (10 days ago) I have been experiencing vertigo and visual disturbances. I stoped the drops and what should I do now.

VISUAL IMPAIRMENT Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Does Oral Sildenafil (Viagra) Decrease Mean Pulmonary Artery Pressure After Cardiac Surgery?
Condition: Pulmonary Hypertension
Interventions: Drug: Sildenafil (Viagra);   Drug: Sildenafil;   Drug: Placebo
Outcome Measures: To determine the efficacy of 12.5mg oral sildenafil to decrease the mPAP in patients presenting with a mPAP >/= 25mmHg after cardiopulmonary bypass.;   To determine the efficacy of a second dose of oral sildenafil 12.5mg to decrease the mPAP in those patients who do not respond with a 20% decrease in mPAP after the initial administration of study medication.;   To determine the safety of oral sildenafil to treat increased mPAP after cardiac surgery.
2 Unknown  Sildenafil for Prevention of Cerebral Vasospasm
Conditions: Subarachnoid Hemorrhage;   Cerebral Vasospasm;   Rupture of Intracranial Aneurysm
Interventions: Drug: Placebo;   Drug: Sildenafil Citrate, 25 mg, 3 times a day.;   Drug: Sildenafil Citrate 50 mg, 3 times a day
Outcome Measures: New neurological Deficit;   Transcranial Ecodoppler;   Mortality;   Side effects;   Time to discharge;   Rankin Scale
3 Unknown  A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
Condition: Erectile Dysfunction
Interventions: Drug: Sildenafil Citrate 20mg Tablet Sublingual;   Drug: Viagra ® 50mg tablet Coated
Outcome Measures: Evaluate a possible superiority expressed by the faster onset of action.;   Evaluate the efficacy and tolerability of Sildenafil Citrate 20mg Sublingual tablet, compared to Viagra ® 50mg tablet Coated in control of Erectile Dysfunction.
4 Recruiting Pharmacokinetics of Sildenafil in Premature Infants
Condition: Persistent Pulmonary Hypertension of the Newborn
Intervention: Drug: 1 dose of sildenafil
Outcome Measures: Area under the plasma concentration versus time curve 0-24 hours for sildenafil;   Peak plasma concentration of sildenafil;   Clearance of sildenafil;   Volume of distribution at steady state;   Half life of sildenafil;   Number of subjects with adverse events as a measure of safety and tolerability.;   Correlation between serum and dried blood spot samples;   Evaluate P450 single nucleotide polymorphisms (SNPs)
5 Unknown  Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS
Condition: Chronic Fatigue Syndrome
Interventions: Drug: Sildenafil (Viagra);   Drug: Placebo
Outcome Measure: The principal aim of this study is to determine whether chronic fatigue syndrome (CFS) is due to inadequate blood flow to the brain and to test a medication, Viagra, which should help increase blood flow to the brain and improve the symptoms of CFS.
6 Unknown  Effects of Viagra on Heart Function in Patients With Heart Failure
Conditions: Heart Failure;   Left Ventricular Dysfunction
Intervention: Drug: sildenafil
Outcome Measures: The primary outcome measure is a fall in the left ventricular filling pressure in association with administration of sildenafil;   A secondary outcome is the distance walked with the 6-minute walk test after the administration of sildenafil
7 Not yet recruiting Effects of Oral Sildenafil on Mortality in Adults With PAH
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: sildenafil citrate
Outcome Measures: Overall Survival (OS);   Time to first clinical worsening (TTCW) event;   6 Minute Walk Distance (6MWD) at Months 6 & 12
8 Recruiting VasoREACTivity Testing With Intravenous SILdenafil in Patients With Precapillary Pulmonary Hypertension
Condition: Pulmonary Hypertension Associated With Connective Tissue Disease
Intervention: Drug: Sildenafil
Outcome Measures: efficacy of Sildenafil I.V. for vasoreactivity testing;   clinical efficacy of sildenafil per os predicted by testing it intravenously in the course of oral therapy
9 Unknown  Early Start of Oral Sildenafil 100mg for Erectile Dysfunction After Robotic Assisted Laparoscopic Radical Prostatectomy
Condition: Prostate Cancer
Intervention: Drug: sildenafil 100mg
Outcome Measures: patterns of recovery of erectile functions after nerve sparing RALP in men with on- demand sildenafil 100mg dosing from the early postoperative period (using IIEF-5);   comparison of the potency rates in men with on- demand sildenafil 100mg dosing from the early postoperative period with from the delayed postoperative period
10 Unknown  Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure
Condition: Heart Failure
Intervention: Drug: Sildenafil
Outcome Measures: Change in 6-minute walk distance;   Changes in peak oxygen consumption (measured by cardiopulmonary exercise testing);   Change in the level of neurohormones (b-type natriuretic peptide, catecholamines, ET-1),;   Change in quality of life
11 Unknown  The Effects of Sildenafil on Exercise Function and Capacity in Patients With Fontan Circulation
Condition: Fontan Circulation
Interventions: Drug: sildenafil;   Other: placebo
Outcome Measure: An increase in exercise capacity for patients administered sildenafil
12 Recruiting The Revaki-001. A Study to Determine the Pharmacokinetic Profile, Safety and Tolerability of Sildenafil (REVATIO®) in Cardiac Surgery
Condition: Acute Kidney Injury
Intervention: Drug: Sildenafil
Outcome Measures: Area under the plasma concentration versus time curve and Plasma Concentration of Sildenafil;   Serum creatinine and Biochemical markers of AKI
13 Recruiting Effects of Sildenafil on Choroidal Thickness in AMD
Condition: Age-related Macular Degeneration
Intervention: Drug: Sildenafil citrate
Outcome Measures: Change in Choroidal Thickness as Assessed on Enhanced-Depth Imaging Optical Coherence Tomography (EDI-OCT);   Change in Central Foveal Thickness as assessed by optical coherence tomography (OCT)
14 Unknown  Viagra for the Treatment of IUGR
Condition: IUGR
Intervention: Drug: Viagra administration in IUGR/PET pregnancies
Outcome Measures: Uteroplacental perfusion;   Fetal growth;   Maternal and fetal safety
15 Not yet recruiting Blood Flow and Vascular Function in Cystic Fibrosis
Condition: Cystic Fibrosis
Interventions: Drug: Acute (1 hour) Sildenafil;   Drug: Sub-Chronic (4 weeks) Sildenafil;   Drug: Placebo
Outcome Measures: Exercise Capacity;   Flow-Mediated Dilation (FMD);   Arterial Stiffness Evaluation (PWV);   Physio Flow
16 Recruiting "As Required" Oral Sildenafil in Raynaud's Phenomenon
Condition: Raynaud's Phenomenon
Interventions: Drug: Sildenafil 40 mg;   Drug: Sildenafil 80 mg;   Drug: Placebo
Outcome Measures: Mean change in the Raynaud's Condition Score (RCS) during treatment, as compared to placebo.;   Frequency of RP: number of RP attacks during treatment, as compared to placebo.;   Patients' preference: comparison between the number of patients favoring a treatment to another.;   Pain associated with RP: Mean change in the Raynaud's pain score during treatment, as compared to placebo.;   Frequency and severity of adverse drug events during treatment, as compared to placebo;   Microvascular reactivity: index of skin perfusion in response to local/regional cooling after a single dose of sildenafil, as compared to placebo (laboratory experiments)
17 Recruiting Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension
Condition: Pulmonary Hypertension
Intervention: Drug: Sildenafil 20mg oral vs Sildenafil 10mg intravenous
Outcome Measure: Effectiveness
18 Recruiting Sildenafil Citrate Before Surgery in Improving Kidney Function in Patients With Kidney Cancer
Condition: Kidney Tumor
Interventions: Drug: sildenafil citrate;   Other: placebo;   Procedure: therapeutic conventional surgery
Outcome Measures: Accrual rate;   Retention rate;   Participation rate;   Change in GFR;   Change in proteinuria;   Estimated blood loss;   Hemoglobin concentration;   Changes in blood pressure measurements;   Vasopressor support requirements during the operative procedure;   Intravenous fluid requirements during the operative procedure;   Overall complication rates;   Preliminary effect size of sildenafil citrate on change in GFR
19 Unknown  On Demand Versus Daily Sildenafil for Patients Undergoing Radical Prostatectomy
Condition: Erectile Dysfunction
Intervention: Drug: Sildenafil
Outcome Measures: Proportion of patients with an Erectile Function domain score of International Index of Erectile Function ( IIEF) => 22 at the end of the wash-out period (44 wks after surgery);   Proportion of patients with an Erectile Function domain score of IIEF => 22 at the end of the study (52 wks after surgery);   IIEF - Domain Scores for: Erection Hardness Score (1-4) Intercourse success rates defined by the Sexual Encounter Profile (SEP) questionnaire (questions 2 and 3) Safety Endpoints: Adverse event summarized Global assessment questions
20 Not yet recruiting Growth Hormone or Sildenafil as Therapies for Fatigue in Mild-​Traumatic-brain-injury (MTBI)
Condition: Traumatic Brain Injury
Interventions: Drug: Growth Hormone;   Drug: Sildenafil;   Drug: Placebo
Outcome Measures: Perceptual fatigue as measured weekly using the Brief Fatigue Inventory;   Performance fatigue as measured by using hand and leg dynamometry.